Table 4.
Treatment variables.
| Total | Control | FIV | FeLV | p Value | ||||
|---|---|---|---|---|---|---|---|---|
| n (%) | n (%) | n (%) | n (%) | p Value | FIV vs. Control | FELV vs. Control | FIV vs. FELV | |
| MTBS | 0.006 # | |||||||
| No | 6 (5%) | 0 (0%) | 4 (14%) | 2 (9%) | 0.010 * | 0.070 | 0.688 | |
| Yes | 105 (95%) | 60 (100%) | 25 (86%) | 20 (91%) | ||||
| Analgesic Opioids | 0.370 | |||||||
| No | 43 (39%) | 20 (33%) | 12 (41%) | 11 (50%) | 0.487 | 0.203 | 0.581 | |
| Yes | 68 (61%) | 40 (67%) | 17 (59%) | 11 (50%) | ||||
| NSAIDs | 0.407 | |||||||
| No | 35 (32%) | 16 (27%) | 10 (34%) | 9 (41%) | 0.465 | 0.280 | 0.772 | |
| Yes | 76 (68%) | 44 (73%) | 19 (66%) | 13 (59%) | ||||
| Oral Gel | 0.007 # | |||||||
| No | 53 (48%) | 23 (38%) | 13 (45%) | 17 (77%) | 0.647 | 0.002 * | 0.025 # | |
| Yes | 58 (52%) | 37 (62%) | 16 (55%) | 5 (23%) | ||||
| Corticosteroids | 0.905 | |||||||
| No | 57 (51%) | 32 (53%) | 14 (48%) | 11 (50%) | 0.821 | 0.808 | 1.000 | |
| Yes | 54 (49%) | 28 (47%) | 15 (52%) | 11 (50%) | ||||
| rHuIFN-α | 0.146 | |||||||
| No | 104 (94%) | 58 (97%) | 25 (86%) | 21 (95%) | 0.085 | 1.000 | 0.375 | |
| Yes | 7 (6%) | 2 (3%) | 4 (14%) | 1 (5%) | ||||
| rFeIFN-ω | 0.403 | |||||||
| No | 97 (87%) | 52 (87%) | 24 (83%) | 21 (95%) | 0.750 | 0.433 | 0.218 | |
| Yes | 14 (13%) | 8 (13%) | 5 (17%) | 1 (5%) | ||||
| Surgery | 0.763 | |||||||
| PME | 53 (48%) | 30 (51%) | 14 (48%) | 9 (41%) | 1.000 | 0.463 | 0.777 | |
| FME | 57 (52%) | 29 (49%) | 15 (52%) | 13 (59%) | ||||
| No. of Phases | 0.437 | |||||||
| 1 | 97 (87%) | 50 (83%) | 27 (93%) | 20 (91%) | 0.323 | 0.499 | 1.000 | |
| 2 | 14 (13%) | 10 (17%) | 2 (7%) | 2 (9%) |
* p ≤ 0.017 was considered significant after Bonferroni correction for multiple comparisons. # p ≤ 0.05.